Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations

NCT03634059 is registered in ClinicalTrials.gov with Hebei Medical University Fourth Hospital as lead sponsor.

NCT NCT03634059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03634059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations
Lead sponsor
Hebei Medical University Fourth Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
August 15, 2018
Completion date
August 15, 2020
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc